Pharma Two B

About

Funding history · 4 rounds · $46.1M total

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is the current operational status of Pharma Two B?

Pharma Two B is currently inactive and ceased to operate in July 2025.

What was the primary reason for Pharma Two B's cessation of operations?

According to a March 2025 report, Pharma Two B requested an opening of proceedings due to a failure in drug manufacturing.

What significant corporate action did Pharma Two B announce in September 2024?

In September 2024, Pharma Two B and Hepion Pharmaceuticals, Inc. announced the filing of a Registration Statement on Form F-4 related to a proposed merger.

What was the strategic intent behind Pharma Two B's proposed merger with Hepion Pharmaceuticals in July 2024?

In July 2024, Pharma Two B viewed the merger with Hepion Pharmaceuticals as a path to go public before seeking FDA approval.

What were the key findings presented by Pharma Two B regarding its P2B001 product in April 2022?

In April 2022, Pharma Two B presented a late-breaker abstract on positive efficacy and safety data of P2B001 from its Phase 3 trial at the American Academy of Neurology (AAN) Annual Meeting.

What were the topline results announced by Pharma Two B in December 2021 for its P2B001 study?

In December 2021, Pharma Two B announced positive topline results from its pivotal Phase III study of P2B001 for early Parkinson's Disease.

What licensing and investment agreement did Pharma Two B secure in November 2021?

In November 2021, Pharma Two B announced a licensing and investment agreement with Myung In Pharm (MIP) for P2B001 in South Korea, which included a $5 million investment.

When did Pharma Two B complete patient enrollment for its Phase III study of P2B001?

In September 2021, Pharma Two B announced the last patient was out in its Phase III study of P2B001 for early Parkinson's Disease.

Who was appointed as CEO of Pharma Two B in January 2021?

In January 2021, Pharma Two B appointed Dr. Sheila Oren as Chief Executive Officer.

When did Pharma Two B begin dosing patients for its Phase III study of P2B001?

In November 2018, Pharma Two B dosed the first patients in its Phase III multi-center, multinational study to determine the efficacy, safety, and tolerability of P2B001 in patients with early-stage Parkinson's Disease.

Sectors & technology

Highlights

Tags